Top

Neurological Sciences

Published in:

04-05-2022 | Smelling Disorder | Original Article

Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson’s disease

Authors: Fardin Nabizadeh, Fatemeh Sodeifian, Kasra Pirahesh

Published in: Neurological Sciences | Issue 8/2022

Abstract

Background

Olfactory dysfunction is one of the earliest non-motor symptoms (NMS) in Parkinson’s disease (PD). There are contradictory results regarding the association of olfactory dysfunction and dopamine uptake in striatal nuclei among PD patients. It has been suggested that different motor subtypes of PD vary in the disease pathophysiology and progression. Thus, we hypothesized that there might be different associations between olfactory dysfunction and striatal dopaminergic neuronal loss among three motor subtypes of PD, namely, indeterminate, postural instability and gait difficulty (PIGD), and tremor-dominant (TD).

Methods

We recruited 162 healthy controls (HCs) and 464 drug-naïve PD patients from PPMI who underwent common PD scaling tests. Striatal binding ratios (SBRs) of DaTSCAN images in caudate and putamen nuclei were calculated. To assess the olfactory function, the University of Pennsylvania Smell Identification Test (UPSIT) was carried out.

Results

The UPSIT score was significantly correlated with MDS-UPDRS part I (p value: 0.002, correlation coefficient: − 0.160), MDS-UPDRS part III (p value: 0.000, correlation coefficient: − 0.248), and SBR score in right (p value: 0.000, correlation coefficient: 0.240) and left caudate (p value: 0.000, correlation coefficient: 0.221) and right (p value: 0.000, correlation coefficient: 0.323) and left putamen (p value: 0.000, correlation coefficient: 0.335) nucleus in TD subtype. There were no significant correlations in HC, PIGD, and indeterminate subjects.

Conclusion

The olfactory dysfunction was correlated with dopamine transporter activity in striatal nuclei only in the TD subtype. Therefore, the olfactory dysfunction in PIGD and indeterminate subtype may not be a predictive factor for the future decrease in dopamine uptake.

Hayes MT (2019) Parkinson’s disease and parkinsonism. Am J Med 132(7):802–807. https://doi.org/10.1016/j.amjmed.2019.03.001CrossRefPubMed

Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6):548–560. https://doi.org/10.1001/jama.2019.22360CrossRefPubMed

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211. https://doi.org/10.1016/s0197-4580(02)00065-9CrossRefPubMed

Eek T, Larsson M, Dizdar N (2021) Odor recognition memory in Parkinson’s disease: a systematic review. Front Aging Neurosci 13:625171–625171. https://doi.org/10.3389/fnagi.2021.625171CrossRefPubMedPubMedCentral

Rossi M, Escobar AM, Bril A, Millar Vernetti P, De Palo JI, Cerquetti D, Merello M (2016) Motor features in Parkinson’s disease with normal olfactory function. Mov Disord 31(9):1414–1417. https://doi.org/10.1002/mds.26687CrossRefPubMed

Yoo HS, Chung SJ, Lee YH, Ye BS, Sohn YH, Lee PH (2020) Association between olfactory deficit and motor and cognitive function in Parkinson’s disease. J Mov Disord 13(2):133–141. https://doi.org/10.14802/jmd.19082CrossRefPubMedPubMedCentral

He R, Zhao Y, He Y, Zhou Y, Yang J, Zhou X, Zhu L, Zhou X, Liu Z, Xu Q, Sun Q, Tan J, Yan X, Tang B, Guo J (2020) Olfactory dysfunction predicts disease progression in Parkinson’s disease a longitudinal study. Front Neurosci 14(1264). https://doi.org/10.3389/fnins.2020.569777

Lee DH, Oh JS, Ham JH, Lee JJ, Lee I, Lee PH, Kim JS, Sohn YH (2015) Is normosmic Parkinson disease a unique clinical phenotype? Neurology 85(15):1270–1275. https://doi.org/10.1212/wnl.0000000000001999CrossRefPubMed

Qian E, Huang Y (2019) Subtyping of Parkinson’s disease - where are we up to? Aging Dis 10 (5) 1130–1139 https://doi.org/10.14336/AD.2019.0112

10.

Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, Stern M, Tanner C, Weiner W, Parkinson Study G (1990) Variable expression of Parkinson’s disease. Neurology 40(10):1529. https://doi.org/10.1212/WNL.40.10.1529CrossRefPubMed

11.

Nutt JG (2016) Motor subtype in Parkinson’s disease: different disorders or different stages of disease? Mov Disord 31(7):957–961. https://doi.org/10.1002/mds.26657CrossRefPubMed

12.

Ren J, Hua P, Li Y, Pan C, Yan L, Yu C, Zhang L, Xu P, Zhang M, Liu W (2020) Comparison of three motor subtype classifications in de novo Parkinson’s disease patients. Front Neurol 11:601225. https://doi.org/10.3389/fneur.2020.601225CrossRefPubMedPubMedCentral

13.

De Pablo-Fernández E, Lees AJ, Holton JL, Warner TT (2019) Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol 76(4):470–479. https://doi.org/10.1001/jamaneurol.2018.4377CrossRefPubMedPubMedCentral

14.

Rezvanian S, Lockhart T, Frames C, Soangra R, Lieberman A (2018) Motor subtypes of Parkinson’s disease can be identified by frequency component of postural stability. Sensors (Basel) 18 (4). https://doi.org/10.3390/s18041102

15.

Grahn JA, Parkinson JA, Owen AM (2009) The role of the basal ganglia in learning and memory: neuropsychological studies. Behav Brain Res 199(1):53–60. https://doi.org/10.1016/j.bbr.2008.11.020CrossRefPubMed

16.

Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46 Suppl 1 (Suppl 1):S30-S33. https://doi.org/10.1016/j.parkreldis.2017.07.033

17.

Sanjari Moghaddam H, Ghazi Sherbaf F, Mojtahed Zadeh M, Ashraf-Ganjouei A, Aarabi MH (2018) Association between peripheral inflammation and DATSCAN data of the striatal nuclei in different motor subtypes of Parkinson disease. Front Neurol 9:234. https://doi.org/10.3389/fneur.2018.00234CrossRefPubMedPubMedCentral

18.

Löhle M, Wolz M, Beuthien-Baumann B, Oehme L, van den Hoff J, Kotzerke J, Reichmann H, Storch A (2020) Olfactory dysfunction correlates with putaminal dopamine turnover in early de novo Parkinson’s disease. J Neural Transm (Vienna) 127(1):9–16. https://doi.org/10.1007/s00702-019-02122-9CrossRef

19.

Oh YS, Kim JS, Hwang EJ, Lyoo CH (2018) Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson’s disease. Parkinsonism Relat Disord 56:47–51. https://doi.org/10.1016/j.parkreldis.2018.06.022CrossRefPubMed

20.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424CrossRefPubMed

21.

Herman T, Weiss A, Brozgol M, Giladi N, Hausdorff JM (2014) Gait and balance in Parkinson’s disease subtypes: objective measures and classification considerations. Journal of Neurology 2014 261:12 261 (12):2401–2410. https://doi.org/10.1007/S00415-014-7513-6

22.

Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC (2013) How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Movement disorders : official journal of the Movement Disorder Society 28(5):668–670. https://doi.org/10.1002/mds.25383CrossRef

23.

Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B (2005) Clinical characteristics in early Parkinson’s disease in a central California population-based study. Mov Disord 20(9):1133–1142. https://doi.org/10.1002/MDS.20513CrossRefPubMedPubMedCentral

24.

Seibyl J, Jennings D, Grachev I, Coffey C, Marek K (2013) 123-I ioflupane SPECT measures of Parkinson disease progression in the Parkinson Progression Marker Initiative (PPMI) trial. J Nucl Med 54(supplement 2):190

25.

Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE (2017) Biomarker-driven phenotyping in Parkinson’s disease: a translational missing link in disease-modifying clinical trials. Movement disorders : official journal of the Movement Disorder Society 32(3):319–324. https://doi.org/10.1002/mds.26913CrossRef

26.

Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel J-P, Fahn S, Eidelberg D (2010) Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 9(2):149–158. https://doi.org/10.1016/S1474-4422(10)70002-8CrossRefPubMedPubMedCentral

27.

Jankovic J, Kapadia AS (2001) Functional decline in Parkinson disease. Arch Neurol 58(10):1611–1615. https://doi.org/10.1001/archneur.58.10.1611CrossRefPubMed

28.

Balint B, Mulroy E, Gövert F, Latorre A, Di Lazarro G, Erro R, Batla A, Holton JL, Miki Y, Warner TT, Bhatia KP (2021) Development of parkinsonism after long-standing cervical dystonia - a cohort. J Neurol Sci 427:117477. https://doi.org/10.1016/j.jns.2021.117477CrossRefPubMed

29.

Rudzińska M, Marona M, Bukowczan S, Banaszkiewicz K, Mirek E, Szczudlik A (2007) Falls in different types of Parkinson’s disease. Neurol Neurochir Pol 41(5):395–403PubMed

30.

Fullard ME, Morley JF, Duda JE (2017) Olfactory dysfunction as an early biomarker in Parkinson’s disease. Neurosci Bull 33(5):515–525CrossRef

31.

Braak H, Del Tredici K, Rüb U, De Vos RA, Steur ENJ, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRef

32.

Hawkes CH, Del Tredici K, Braak H (2010) A timeline for Parkinson’s disease. Parkinsonism Relat Disord 16(2):79–84CrossRef

33.

Beach TG, White CL, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J (2009) Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 117(2):169–174CrossRef

34.

Modugno N, Lena F, Di Biasio F, Cerrone G, Ruggieri S, Fornai F (2013) A clinical overview of non-motor symptoms in Parkinson’s disease. Arch Ital Biol 151(4):148–168PubMed

35.

Oh Y-S, Kim J-S, Yoo S-W, Hwang E-J, Lyoo CH, Lee K-S (2019) Striatal dopamine activity and myocardial 123I-metaiodobenzylguanidine uptake in early Parkinson’s disease. Parkinsonism Relat Disord 63:156–161CrossRef

36.

Siderowf A, Newberg A, Chou K, Lloyd M, Colcher A, Hurtig H, Stern M, Doty R, Mozley P, Wintering N (2005) [99mTc] TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 64(10):1716–1720CrossRef

37.

Berendse HW, Roos DS, Raijmakers P, Doty RL (2011) Motor and non-motor correlates of olfactory dysfunction in Parkinson’s disease. J Neurol Sci 310(1–2):21–24CrossRef

38.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K, Investigators P (2014) Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study. Neurology 83(19):1739–1746CrossRef

39.

Daalen JMJ, Tosserams A, Mahlknecht P, Seppi K, Bloem BR, Darweesh SK (2021) Towards subgroup-specific risk estimates: a meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson’s disease. Parkinsonism & Related Disorders

40.

Lee JW, Song YS, Kim H, Ku BD, Lee WW (2019) Alteration of tremor dominant and postural instability gait difficulty subtypes during the progression of Parkinson’s disease: analysis of the PPMI cohort. Front Neurol 10:471. https://doi.org/10.3389/fneur.2019.00471CrossRefPubMedPubMedCentral

41.

Nabizadeh F, Pirahesh K, Khalili E (2022) Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease. Neurol Sci. https://doi.org/10.1007/s10072-022-05952-wCrossRefPubMed

Title: Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson’s disease
Authors: Fardin Nabizadeh
Fatemeh Sodeifian
Kasra Pirahesh
Publication date: 04-05-2022
Publisher: Springer International Publishing
Keywords: Smelling Disorder
Tremor
Smelling Disorder
Parkinson's Disease
Published in: Neurological Sciences / Issue 8/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06110-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson’s disease

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2022

Vincenzo Neri (1880–1960) and his sign to detect leg weakness due to corticospinal tract injury

Striatal dopamine transporter imaging in Parkinson’s disease drug-naïve patients: focus on sexual dysfunction

A snapshot of emergency neurology management in the Lombardy Region, Italy

Plasma arylsulfatase A levels are associated with cognitive function in Parkinson’s disease

High rates of blood transfusion associated with Parkinson’s disease

Gene analysis and clinical features of 22 GNE myopathy patients